R1 Therapeutics Launches with $77.5M Series A to Advance CKD Treatment
Redwood City, CA – March 17, 2026 – R1 Therapeutics has officially emerged from stealth mode, announcing an oversubscribed...
CKD
Advertisement
Renalys Reports Strong Phase III Results for Sparsentan in IgAN
Tokyo, Japan, November 26 2025 — Renalys Pharma has announced positive topline results from its Phase III clinical study...
Baxdrostat Achieves Primary Endpoint in Phase III Trial for rHTN
SLondon, UK – October 7, 2025 – AstraZeneca announced that Baxdrostat met the primary endpoint in the Bax24 Phase...
Advertisement
